What does this research mean for the field?

Question

Accepted Answer

Disease recurrence after initial pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma is likely driven by a diminishing therapy-induced immune response rather than genetic changes mediating tumor immune evasion. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma

Discussion

Member takes

Overview

Key Points

Cite This Study